IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates are darovasertib (IDE196), IDE397, IDE161 and GSK101 (Pol Theta Helicase). IDE196, a small molecule protein kinase C (PKC), inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397, is its small molecule methionine adenosyltransferase 2a (MAT2A), inhibitor. IDE161, is its small molecule poly (ADP-ribose) glycohydrolase (PARG), inhibitor. IDE196 is its clinical-stage PKC inhibitor that the Company is evaluating as a synthetic lethal combination therapy. IDE397, a MAT2A inhibitor for patients with solid tumors having MTAP deletions. IDE161 is its clinical-stage, potent and selective small molecule inhibitor of PARG for patients having tumors with defined biomarkers based on genetic mutations and/or molecular signatures.

Employees

145

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
16/03/26	34.79 $	+5.14%	696,082
13/03/26	33.09 $	+0.79%	812,928
12/03/26	32.83 $	-3.58%	500,352
11/03/26	34.05 $	-1.99%	457,448
10/03/26	34.74 $	-0.97%	983,237

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

34.79USD

Average target price

50.00USD

Spread / Average Target

+43.72%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 20:00:00 16/03/2026 GMT			5-day change	1st Jan Change
34.79 ^USD	+5.14%		-0.83%	+0.64%

03-09	IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, Potential PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update	CI
03-09	Ideaya Biosciences Says 1st Patient Enrolled in Phase 1 Clinical Trial of Solid Tumors; Shares Up Pre-Bell	MT

Capitalization	3.06B 2.66B 2.41B 2.3B 4.18B 282B 4.34B 28.63B 11.38B 135B 11.46B 11.22B 487B	P/E ratio 2026 *	-8.7x	P/E ratio 2027 *	-10.1x
Enterprise value	2.03B 1.77B 1.6B 1.53B 2.78B 187B 2.88B 19.01B 7.56B 89.62B 7.61B 7.45B 323B	EV / Sales 2026 *	53.6x	EV / Sales 2027 *	19.6x
Free-Float	98.96%	Yield 2026 *	-	Yield 2027 *	-

03-09	IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, Potential PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update	CI
03-09	Ideaya Biosciences Says 1st Patient Enrolled in Phase 1 Clinical Trial of Solid Tumors; Shares Up Pre-Bell	MT
03-09	Ideaya Biosciences announces first-patient-in for phase 1 trial of IDE892	RE
03-03	Ideaya Biosciences Insider Bought Shares Worth $1,647,890, According to a Recent SEC Filing	MT
02-28	Biocytogen Pharmaceuticals Co., Ltd. Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of Ide034	CI
02-27	Ideaya Biosciences announces inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
02-25	Ideaya Biosciences Says First Patient Dosed in Early-Stage Trial of IDE034	MT
02-25	IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific Top1 ADC	CI
02-25	Ideaya Biosciences announces first-patient-in for phase 1 trial of IDE034, a potential first-in-class B7h3/Ptk7 bispecific Top1 ADC	RE
02-23	IDEAYA Biosciences, Inc. - Special Call
02-23	IDEAYA Biosciences, Inc. Announces Appointment of Dr. Theodora Ross, M.D., Ph.D., as Chief Development Officer	CI
02-23	Ideaya Biosciences announces appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as chief development officer	RE
02-18	IDEAYA Biosciences, Inc. Presents at Citi?s 2026 Virtual Oncology Leadership Summit, Feb-18-2026 01:00 PM

02-18	Wedbush Adjusts Price Target on IDEAYA Biosciences to $52 From $49, Maintains Outperform Rating	MT
02-17	Wedbush Adjusts IDEAYA Biosciences Price Target to $52 From $49, Maintains Outperform Rating	MT
01-21	RBC Raises Price Target on IDEAYA Biosciences to $45 From $41, Keeps Outperform, Speculative Risk	MT
11-10	Mizuho Raises Price Target on IDEAYA Biosciences to $46 From $44, Keeps Outperform Rating	MT
21/10/25	RBC Raises Price Target on IDEAYA Biosciences to $41 From $38, Keeps Outperform, Speculative Risk	MT

IDEAYA Biosciences, Inc. Share Price

Equities

IDYA

US45166A1025

Biotechnology & Medical Research

Valuation: IDEAYA Biosciences, Inc.

Chart: IDEAYA Biosciences, Inc.

Latest news: IDEAYA Biosciences, Inc.

Last Transcript: IDEAYA Biosciences, Inc.

Analysts' recommendations: IDEAYA Biosciences, Inc.

Press Releases: IDEAYA Biosciences, Inc.

News in other languages: IDEAYA Biosciences, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: IDEAYA Biosciences, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

03-09	IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update	PR
03-02	Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA's First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034	AQ
03-02	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(4)	AQ
02-27	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	PR
02-25	IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC	PR

11/11/24	Biocytogen kündigt die Nominierung des Entwicklungskandidaten IDE034 von IDEAYA, einem potenziellen ersten bispezifischen ADC (Antibody Drug Conjugate, Antikörper-Wirkstoff-Konjugat) der Klasse B7H3/PTK7 Topo-I-Nutzlast, sowie die Ausübung der...
11/11/24	Biocytogen annonce la nomination par IDEAYA du candidat IDE034, un ADC bispécifique Topo-I-Payload B7H3/PTK7, ainsi que la levée d’une option
08/07/24	MÄRKTE USA/Kaum Bewegung - S&P-500 und Nasdaq mit neuen Rekordhochs
08/07/24	MÄRKTE USA/Wenig verändert - S&P-500 und Nasdaq mit neuen Rekordhochs
08/07/24	MÄRKTE USA/Dow maschiert vorneweg - S&P-500 und Nasdaq mit Rekorden

1 day	+5.14%
1 week	-0.83%
Current month	+8.04%
1 month	+14.93%
3 months	+2.90%
6 months	+40.74%
Current year	+0.64%

1 week	32.15	35.11
1 month	30.53	35.68
Current year	29.47	39.28
1 year	13.45	39.28
3 years	13.29	47.74
5 years	8.14	47.74
10 years	2.95	47.74

Manager	Title	Age	Since
Yujiro Hata CEO	Chief Executive Officer	51	31/05/2015
Michael White CTO	Chief Tech/Sci/R&D Officer	61	31/10/2021
Paul A. Barsanti CTO	Chief Tech/Sci/R&D Officer	-	28/02/2023

Director	Title	Age	Since
Yujiro Hata BRD	Director/Board Member	51	31/05/2015
Terry Rosen CHM	Chairman	68	-
Jeffrey Stein BRD	Director/Board Member	71	30/09/2015

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
IDEAYA BIOSCIENCES, INC.	+5.14%	-0.83%	+87.24%	+120.75%	3.06B
LONZA GROUP AG	-0.03%	-3.06%	-14.05%	-9.80%	42.95B
BEONE MEDICINES AG	+1.97%	-4.18%	+11.75%	+28.87%	32.12B
CELLTRION, INC.	-2.68%	-1.96%	+11.77%	+44.06%	29.32B
IQVIA HOLDINGS INC.	+0.10%	-7.65%	-10.96%	-16.06%	27.68B
REVOLUTION MEDICINES, INC.	+4.36%	-0.79%	+153.07%	+345.14%	19.62B
ASCENDIS PHARMA A/S	+2.23%	-3.71%	+51.02%	+110.62%	14.18B
MEDPACE HOLDINGS, INC.	+0.72%	-5.20%	+39.60%	+148.90%	12.87B
EUROFINS SCIENTIFIC SE	+0.95%	-2.80%	+23.37%	+0.88%	12.39B
IONIS PHARMACEUTICALS, INC.	+1.62%	-4.01%	+119.48%	+106.69%	11.95B
Average	+1.44%	-3.61%	+47.23%	+88.00%	20.61B
Weighted average by Cap.	+0.77%	-3.89%	+29.28%	+64.35%

	2026 *	2027 *
Net sales	37.88M 33M 29.88M 28.5M 51.85M 3.5B 53.76M 355M 141M 1.67B 142M 139M 6.04B	121M 105M 95.29M 90.91M 165M 11.15B 171M 1.13B 450M 5.34B 453M 444M 19.25B
Net income	-361M -314M -284M -271M -494M -33.29B -512M -3.38B -1.34B -15.93B -1.35B -1.32B -57.45B	-327M -285M -258M -246M -448M -30.19B -464M -3.06B -1.22B -14.44B -1.23B -1.2B -52.1B
Net Debt	-1.03B -894M -809M -772M -1.4B -94.72B -1.46B -9.61B -3.82B -45.32B -3.85B -3.77B -163B	-686M -598M -541M -516M -939M -63.35B -974M -6.43B -2.56B -30.31B -2.58B -2.52B -109B